138 related articles for article (PubMed ID: 19020294)
1. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias.
Troiano AR; de la Fuente-Fernandez R; Sossi V; Schulzer M; Mak E; Ruth TJ; Stoessl AJ
Neurology; 2009 Apr; 72(14):1211-6. PubMed ID: 19020294
[TBL] [Abstract][Full Text] [Related]
2. Age and severity of nigrostriatal damage at onset of Parkinson's disease.
De La Fuente-Fernández R; Lim AS; Sossi V; Adam MJ; Ruth TJ; Calne DB; Stoessl AJ; Lee CS
Synapse; 2003 Feb; 47(2):152-8. PubMed ID: 12454953
[TBL] [Abstract][Full Text] [Related]
3. Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients: positron emission tomographic studies.
Koochesfahani KM; de la Fuente-Fernández R; Sossi V; Schulzer M; Yatham LN; Ruth TJ; Blinder S; Stoessl AJ
Mov Disord; 2006 Jul; 21(7):970-5. PubMed ID: 16570297
[TBL] [Abstract][Full Text] [Related]
4. Dopamine transporter PET in normal aging: dopamine transporter decline and its possible role in preservation of motor function.
Troiano AR; Schulzer M; de la Fuente-Fernandez R; Mak E; McKenzie J; Sossi V; McCormick S; Ruth TJ; Stoessl AJ
Synapse; 2010 Feb; 64(2):146-51. PubMed ID: 19852071
[TBL] [Abstract][Full Text] [Related]
5. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.
Lee CS; Samii A; Sossi V; Ruth TJ; Schulzer M; Holden JE; Wudel J; Pal PK; de la Fuente-Fernandez R; Calne DB; Stoessl AJ
Ann Neurol; 2000 Apr; 47(4):493-503. PubMed ID: 10762161
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease.
Bohnen NI; Albin RL; Koeppe RA; Wernette KA; Kilbourn MR; Minoshima S; Frey KA
J Cereb Blood Flow Metab; 2006 Sep; 26(9):1198-212. PubMed ID: 16421508
[TBL] [Abstract][Full Text] [Related]
7. Imaging in Parkinson's disease: the role of monoamines in behavior.
Brooks DJ; Piccini P
Biol Psychiatry; 2006 May; 59(10):908-18. PubMed ID: 16581032
[TBL] [Abstract][Full Text] [Related]
8. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation.
Adams JR; van Netten H; Schulzer M; Mak E; Mckenzie J; Strongosky A; Sossi V; Ruth TJ; Lee CS; Farrer M; Gasser T; Uitti RJ; Calne DB; Wszolek ZK; Stoessl AJ
Brain; 2005 Dec; 128(Pt 12):2777-85. PubMed ID: 16081470
[TBL] [Abstract][Full Text] [Related]
9. Putaminal serotonergic innervation: monitoring dyskinesia risk in Parkinson disease.
Lee JY; Seo S; Lee JS; Kim HJ; Kim YK; Jeon BS
Neurology; 2015 Sep; 85(10):853-60. PubMed ID: 26253444
[TBL] [Abstract][Full Text] [Related]
10. Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study.
Sossi V; de la Fuente-Fernández R; Schulzer M; Troiano AR; Ruth TJ; Stoessl AJ
Ann Neurol; 2007 Nov; 62(5):468-74. PubMed ID: 17886297
[TBL] [Abstract][Full Text] [Related]
11. Progression of dopaminergic depletion in a model of MPTP-induced Parkinsonism in non-human primates. An (18)F-DOPA and (11)C-DTBZ PET study.
Blesa J; Juri C; Collantes M; Peñuelas I; Prieto E; Iglesias E; Martí-Climent J; Arbizu J; Zubieta JL; Rodríguez-Oroz MC; García-García D; Richter JA; Cavada C; Obeso JA
Neurobiol Dis; 2010 Jun; 38(3):456-63. PubMed ID: 20304066
[TBL] [Abstract][Full Text] [Related]
12. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.
de la Fuente-Fernández R; Sossi V; Huang Z; Furtado S; Lu JQ; Calne DB; Ruth TJ; Stoessl AJ
Brain; 2004 Dec; 127(Pt 12):2747-54. PubMed ID: 15329355
[TBL] [Abstract][Full Text] [Related]
13. Can early dopamine transporter imaging serve as a predictor of Parkinson's disease progression and late motor complications?
Djaldetti R; Rigbi A; Greenbaum L; Reiner J; Lorberboym M
J Neurol Sci; 2018 Jul; 390():255-260. PubMed ID: 29801899
[TBL] [Abstract][Full Text] [Related]
14. Putaminal dopamine turnover in de novo Parkinson disease predicts later motor complications.
Löhle M; Mende J; Wolz M; Beuthien-Baumann B; Oehme L; van den Hoff J; Kotzerke J; Reichmann H; Storch A
Neurology; 2016 Jan; 86(3):231-40. PubMed ID: 26718573
[TBL] [Abstract][Full Text] [Related]
15. [11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease.
Kumar A; Mann S; Sossi V; Ruth TJ; Stoessl AJ; Schulzer M; Lee CS
Brain; 2003 Dec; 126(Pt 12):2648-55. PubMed ID: 12937076
[TBL] [Abstract][Full Text] [Related]
16. In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133.
Okamura N; Villemagne VL; Drago J; Pejoska S; Dhamija RK; Mulligan RS; Ellis JR; Ackermann U; O'Keefe G; Jones G; Kung HF; Pontecorvo MJ; Skovronsky D; Rowe CC
J Nucl Med; 2010 Feb; 51(2):223-8. PubMed ID: 20080893
[TBL] [Abstract][Full Text] [Related]
17. Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography.
Hsiao IT; Weng YH; Hsieh CJ; Lin WY; Wey SP; Kung MP; Yen TC; Lu CS; Lin KJ
JAMA Neurol; 2014 Jun; 71(6):758-66. PubMed ID: 24756323
[TBL] [Abstract][Full Text] [Related]
18. In vivo detection of monoaminergic degeneration in early Parkinson disease by (18)F-9-fluoropropyl-(+)-dihydrotetrabenzazine PET.
Lin SC; Lin KJ; Hsiao IT; Hsieh CJ; Lin WY; Lu CS; Wey SP; Yen TC; Kung MP; Weng YH
J Nucl Med; 2014 Jan; 55(1):73-9. PubMed ID: 24287322
[TBL] [Abstract][Full Text] [Related]
19. Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias.
Cheshire P; Ayton S; Bertram KL; Ling H; Li A; McLean C; Halliday GM; O'Sullivan SS; Revesz T; Finkelstein DI; Storey E; Williams DR
Mov Disord; 2015 May; 30(6):796-804. PubMed ID: 25649148
[TBL] [Abstract][Full Text] [Related]
20. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging.
Frey KA; Koeppe RA; Kilbourn MR; Vander Borght TM; Albin RL; Gilman S; Kuhl DE
Ann Neurol; 1996 Dec; 40(6):873-84. PubMed ID: 9007092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
